NOVAVAX $NVAX Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $57M (Est. $52.5M) 🟢; -76% YoY 🔹 EPS: -$0.32 (Est. -$0.39) 🟢; -148% YoY 🔹 Net Loss: -$53M 🔹 Product Sales: $19M; +76% YoY FY26 Guide: 🔹 Adjusted Total Revenue: $235M-$275M 🔹 Combined R&D and SG&A: $370M-$410M 🔹 Non-GAAP Combined R&D and SG&A: $310M-$340M 🔹 Nuvaxovid Product Sales: $35M-$45M 🔹 Adjusted Supply Sales: $45M-$55M 🔹 Adjusted Licensing, Royalties and Other Revenue: $155M-$175M Segment Net Revenue: 🔹 Product Sales: $19M; +76% YoY 🔹 Licensing, Royalties and Other Revenue: $38M; -83% YoY 🔹 Sanofi: $36M; -82% YoY 🔹 Supply Sales: $19M; +47% YoY Other Q2 Metrics: 🔹 Cash: $724M 🔹 R&D Expenses: $71M 🔹 SG&A Expenses: $27M; -39% YoY Comments: 🔸 “we believe we are well positioned to deliver several important partner milestones”